Thai Fund Invests in German Deep Tech Startup DiaMonTech
Investment Supports Non-Invasive Glucose Measurement Technology
Thailand's Disrupt Health Impact Fund has made its inaugural investment in DiaMonTech, a German deep tech startup known for developing a non-invasive blood glucose measurement device.
This investment was part of a fundraising round that raised approximately $5 million.
DiaMonTech, which previously secured $20 million from investors including Samsung Venture and Medtronic, plans to commercialize its innovative technology by 2025.
Krating Poonpol, chairman of Disrupt Health Impact Fund, highlights the alignment with global trends in health tech and self-care.
The technology is seen as having significant potential for global expansion, targeting both diabetic patients and health-conscious consumers.
The self-care medical device market is projected to grow from $24.4 billion in 2023 to $42.6 billion by 2032.
Jantanarak Tuekaew, partner at the fund, emphasizes the convenience of DiaMonTech's device, which provides glucose readings in 30 seconds without traditional blood draws, benefiting over 530 million diabetics worldwide.
The device, named D-pocket, is awaiting FDA approval ahead of its market launch.
Thorsten Lubinski, DiaMonTech’s CEO, anticipates the partnership with the Thai fund will facilitate expansion throughout Southeast Asia.
This investment was part of a fundraising round that raised approximately $5 million.
DiaMonTech, which previously secured $20 million from investors including Samsung Venture and Medtronic, plans to commercialize its innovative technology by 2025.
Krating Poonpol, chairman of Disrupt Health Impact Fund, highlights the alignment with global trends in health tech and self-care.
The technology is seen as having significant potential for global expansion, targeting both diabetic patients and health-conscious consumers.
The self-care medical device market is projected to grow from $24.4 billion in 2023 to $42.6 billion by 2032.
Jantanarak Tuekaew, partner at the fund, emphasizes the convenience of DiaMonTech's device, which provides glucose readings in 30 seconds without traditional blood draws, benefiting over 530 million diabetics worldwide.
The device, named D-pocket, is awaiting FDA approval ahead of its market launch.
Thorsten Lubinski, DiaMonTech’s CEO, anticipates the partnership with the Thai fund will facilitate expansion throughout Southeast Asia.
